Recent News

BAP1 and Mesothelioma Risk

March 17, 2023

Researchers have found at least one way that asbestos causes mesothelioma. The disease is linked to the HMGB1 protein. Researchers looked at a mesothelioma epidemic in Türkiye, noting that in…

Accelerated Hypofractionated Radiotherapy for Mesothelioma

March 10, 2023

A recent study from Italy found that accelerated hypofractionated radiotherapy could be an effective treatment for mesothelioma. This is good news for people suffering from the rare and aggressive cancer.…

A Vaccine to Prevent and Treat Mesothelioma Could be Possible in the Future

March 3, 2023

A vaccine for lung cancer could possibly lead to a vaccine for mesothelioma. The lung cancer immunotherapy drug CIMAvax-EFG is making great progress, and because of this progress, researchers are…

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

February 24, 2023

Primary Outcome Measures Phase 1 Maximum Tolerated Dose [ Time Frame: 28 days ] To determine the maximum tolerated dose (MTD) of TNG462 Phase 1 Dosing Schedule [ Time Frame: 28 days ] To determine the dosing schedule…

Gene Suppressor Therapy Could Improve Survival for Mesothelioma Patients

February 24, 2023

New mesothelioma research is being performed at The Netherlands Cancer Institute. The researchers are looking at new combinations of medications to be used on patients that have mesothelioma with BAP1…

Using MicroRNA as a Biomarker to Diagnose Mesothelioma

February 17, 2023

The early diagnosis and treatment of mesothelioma is critical for extending survival in patients. Researchers in Italy may have found a helpful biomarker to catch mesothelioma earlier, up to five…

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

February 10, 2023

Primary Outcome Measures Number of patients tolerating dose levels (maximum tolerated dose; MTD) in each of the combinations [ Time Frame: Assessed from baseline to 30 days after last dose of study drug ]…

Cytokine Factories to Treat Pleural and Peritoneal Mesothelioma

February 10, 2023

A new study from Rice University in Houston is showing promising results for mesothelioma. It utilizes the immune system to fight cancer cells. The protein that is being studied is…

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

February 3, 2023

Primary Outcome Measures Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [ Time Frame: through study completion; an average of…

Opdivo and Yervoy After Mesothelioma Surgery Improves Survival

February 3, 2023

There might be more options for treating mesothelioma. A study looked at the combination of Opdivo and Yervoy after surgery. The study was performed at the Hyogo College of Medicine…